Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Sub-Study.

[1]  A. Natali,et al.  Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study , 2020, Journal of cardiovascular medicine.

[2]  S. Larsson,et al.  Causal associations of thyroid function and dysfunction with overall, breast and thyroid cancer: A two-sample Mendelian randomization study , 2020, International journal of cancer.

[3]  C. O'connor,et al.  Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. , 2019, Journal of cardiac failure.

[4]  P. Ponikowski,et al.  The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study , 2019, European journal of heart failure.

[5]  C. O'connor,et al.  Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. , 2018, Journal of cardiac failure.

[6]  J. McMurray,et al.  Increased mortality with elevated plasma endothelin‐1 in acute heart failure: an ASCEND‐HF biomarker substudy , 2016, European journal of heart failure.

[7]  C. O'connor,et al.  Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. , 2015, JACC. Heart failure.

[8]  R. Califf,et al.  Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). , 2015, JACC. Heart failure.

[9]  D. Mann.  Innate immunity and the failing heart: the cytokine hypothesis revisited. , 2015, Circulation research.

[10]  R. Califf,et al.  High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. , 2014, Journal of cardiac failure.

[11]  T. Ueland,et al.  Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure , 2014, Current Heart Failure Reports.

[12]  Meixiang Xiang,et al.  Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction , 2014, Heart Failure Reviews.

[13]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[14]  V. Hasselblad,et al.  Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study , 2011, European journal of heart failure.

[15]  L. Deckelbaum,et al.  Effect of nesiritide in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[16]  J. Heywood,et al.  Modulation of Novel Cardiorenal and Inflammatory Biomarkers by Intravenous Nitroglycerin and Nesiritide in Acute Decompensated Heart Failure: An Exploratory Study , 2011, Circulation. Heart failure.

[17]  M. Laakso,et al.  Prognostic role of pro‐ and anti‐inflammatory cytokines and their polymorphisms in acute decompensated heart failure , 2008, European journal of heart failure.

[18]  J. Todd,et al.  Ultrasensitive flow-based immunoassays using single-molecule counting. , 2007, Clinical chemistry.

[19]  P. Lasierra,et al.  Time-course of changes in levels of interleukin 6 in acutely decompensated heart failure. , 2006, International journal of cardiology.

[20]  T. Katagiri,et al.  Time-course of changes in the levels of interleukin 6 in acutely decompensated heart failure. , 2005, International journal of cardiology.

[21]  T. Kanda,et al.  Interleukin-6 and cardiovascular diseases. , 2004, Japanese heart journal.

[22]  H. Drexler,et al.  The Role of Interleukin-6 in the Failing Heart , 2001, Heart Failure Reviews.

[23]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[24]  P. Gabriele,et al.  Activation of the cardiac interleukin‐6 system in advanced heart failure , 2001 .

[25]  M. Kinoshita,et al.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[26]  F. Villarreal,et al.  Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes , 2000, Basic Research in Cardiology.

[27]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[28]  G. MacGowan,et al.  Circulating interleukin-6 in severe heart failure. , 1997, The American journal of cardiology.

[29]  G. Breithardt,et al.  Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. , 1996, International journal of cardiology.

[30]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.